On Monday, Deutsche Bank updated its stance on argenx SE (ARGX:BB) (NASDAQ: ARGX), raising the price target to €525.00 from the previous €500.00 while maintaining a Hold rating on the stock. The adjustment follows a strong financial performance by the company, which challenged the bank's earlier valuation concerns.
The decision to increase the price target comes after argenx reported a robust quarter that surpassed the bank's expectations. In a previous assessment dated October 3, 2024, Deutsche Bank had downgraded the stock to Hold with an unchanged price target of €500.00, citing a balanced risk-reward scenario post-achievement of the target price.
The downgrade was not a reflection on the company's fundamentals but was influenced by moderating trends for argenx's drug Vygvart and the anticipation surrounding the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) launch.
Deutsche Bank acknowledged that their earlier downgrade may have been somewhat premature as argenx has demonstrated a promising start with its CIDP launch. This successful launch has sparked discussions on the potential growth and reach of the drug, especially given the current lack of direct competition in the CIDP market. This contrasts with the Myasthenia Gravis (MG) market, where multiple drugs targeting FcRn and complement pathways are emerging.
The analyst pointed out that while the fundamental view of argenx remains unchanged, the company's recent performance and CIDP launch success have warranted a reevaluation of the stock's price target. However, despite the positive start for CIDP, the bank maintains a cautious stance due to the high investor expectations and the absence of significant clinical catalysts expected through the fiscal year 2025.
In other recent news, Argenx SE has experienced robust sales of Vyvgart and Vyvgart Hytrulo, leading to significant earnings and revenue results. The company's third-quarter net product revenue reached $573 million, surpassing estimates set by Oppenheimer and consensus forecasts.
Argenx's recent product launch, Vyvgart Hytrulo, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), has been well-received in the market. Analyst firms such as Oppenheimer, Piper Sandler, Leerink Partners, and H.C. Wainwright have increased their price targets for Argenx shares, citing the company's impressive quarterly earnings.
However, Baird downgraded Argenx to Neutral, suggesting limited short-term upside, while William Blair upgraded the stock to Outperform, acknowledging the success of the Vyvgart franchise. The company also reported an operating income of $589 million, primarily driven by Vyvgart sales, despite recording a year-to-date operating loss. Argenx recently launched Vyvgart for CIDP, with regulatory reviews ongoing in China, Japan, and Europe, and approvals anticipated in 2025.
InvestingPro Insights
argenx SE's recent performance aligns with Deutsche Bank's updated outlook. According to InvestingPro data, the company's revenue growth is impressive, with an 85.56% increase in the last twelve months as of Q3 2024. This robust growth supports the bank's decision to raise the price target.
InvestingPro Tips highlight that argenx holds more cash than debt on its balance sheet, which could provide financial flexibility for future growth initiatives, including the expansion of its CIDP drug. Additionally, the stock is trading near its 52-week high, reflecting investor confidence in the company's recent successes.
It's worth noting that while argenx is not currently profitable, analysts predict the company will be profitable this year. This aligns with Deutsche Bank's cautious optimism and the maintained Hold rating. For investors seeking a deeper understanding of argenx's potential, InvestingPro offers 11 additional tips that could provide valuable insights into the company's future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.